

A Community Based Primary Prevention Programme for Type 2 Diabetes Integrating Identification and Lifestyle Intervention for Prevention: the Let's Prevent Diabetes Cluster Randomised Controlled Trial

Melanie J Davies^{a,b}, Laura J Gray^c, Jacqui Troughton^d, Alastair Gray^e, Jaakko Tuomilehto^{f-h}, Azhar Farooqi^a, Kamlesh Khunti^a, Thomas Yates^{a,b}, on behalf of the Let's Prevent Diabetes Team.

^aDiabetes Research Centre, University of Leicester, Leicester, UK. ^b Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, Leicester, UK. ^cDepartment of Health Sciences, University of Leicester, Leicester, UK. ^dLeicester Diabetes Centre, University Hospitals of Leicester, Leicester, UK. ^eHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. ^fCentre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria. ^gDepartment of Chronic Disease Prevention, National Institute for Health and Welfare, 00271 Helsinki, Finland. ^hDiabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia

Email addresses: melanie.davies@uhl-tr.nhs.uk; lg48@le.ac.uk; Jacqui.Troughton@uhl-tr.nhs.uk; alastair.gray@dph.ox.ac.uk; jaakko.tuomilehto@thl.fi; azhar_farooqi@hotmail.com; kk22@le.ac.uk; ty20@le.ac.uk

Word counts:

Abstract: 249

Main text: 3502

Corresponding author:

Dr Laura Gray, lg48@leicester.ac.uk

Leicester Diabetes Centre (Bloom), Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW, UK.

ABSTRACT

Aims: Prevention of type 2 diabetes (T2DM) is a priority in healthcare, but there is a lack of evidence investigating how to effectively translate prevention research into a UK primary care setting. We assessed whether a structured education programme targeting lifestyle and behaviour change was effective at preventing progression to T2DM in people with prediabetes..

Materials and methods: 44 General Practices were randomised to receive either standard care or a six hour group structured education programme with an annual refresher course, and regular phone contact. Participants were followed up for 3 years. The primary outcome was progression to T2DM.

Results: Eight hundred and eighty participants were included (36% female, mean age 64 years, 16% ethnic minority group); 131 participants developed T2DM. There was a non-significant 26% reduced risk of developing T2DM in the intervention arm compared to standard care (HR 0.74, 95%CI 0.48, 1.14, p=0.18). The reduction in T2DM risk when excluding those who did not attend the initial education session was also non-significant (HR 0.65, 0.41, 1.03, p=0.07). There were statistically significant improvements in HbA1c (-0.06, -0.11, -0.01), LDL cholesterol (-0.08, -0.15, -0.01), sedentary time (-26.29, -45.26, -7.32) and step count (498.15, 162.10, 834.20) when data were analysed across all time points.

Conclusions: This study suggests that a relatively low resource, pragmatic diabetes prevention programme resulted in modest benefits to biomedical, lifestyle and psychosocial outcomes, however the reduction to the risk of T2DM did not reach significance. The findings have important implications for future research and primary care.

Trial Registration: ISRCTN80605705

Keywords: Type 2 diabetes, pre-diabetes. prevention, lifestyle, clinical trial

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is associated with reduced quality of life and serious complications. The life expectancy of individuals with T2DM may be shortened by as much as ten years, with most dying of cardiovascular diseases (CVD).(1) The management of T2DM consumes around 10% of health care expenditure.(2) Consequently, the prevention of T2DM is a priority and has been highlighted by the NHS, UK, as one of four priority areas.(3)

Prediabetes (PDM) is a high-risk state where glucose levels are elevated but do not reach the threshold for diagnosis of T2DM. Trials have unequivocally demonstrated that lifestyle interventions, which promote moderate to vigorous-intensity physical activity, a healthy diet and weight regulation, reduce the risk of progressing to T2DM by 30-60% in those with PDM.(4) For example, the Finnish Diabetes Prevention Study (DPS) found that the risk of T2DM was reduced by 58% in those referred to an intensive lifestyle intervention compared to usual care over a three-year period.(5) Consistent findings have been reported from the USA Diabetes Prevention Program (DPP).(6)

Despite the strong evidence for lifestyle interventions in the prevention of T2DM, there has been a translational gap between trial evidence and implementation into routine care. This is predominantly due to the resource-intensive nature of lifestyle interventions tested. For example, in the first year of the DPP programme, participants received 16 one hour one-to-one counselling sessions followed by an average of eight additional contacts and two telephone consultations. Participants were also offered supervised exercise classes.(6) This intensity of care is incompatible with routine care pathways. Therefore, the emphasis needs to be shifted to examining the effectiveness of approaches designed for implementation within routine primary care. As healthcare services have differences in funding, organisation and infrastructure, programmes cannot be assumed to be generalizable across contexts. To date there has been a dearth of evidence concerning T2DM prevention in the UK, with small-scale projects showing mixed results.(7-10)

This study assesses whether the Let's Prevent T2DM programme is effective at preventing progression to T2DM in people with PDM identified through a systematic screening pathway within primary care. Let's Prevent is a pragmatic, relatively low resource, group-based

structured-education programme targeting lifestyle behaviour change specifically designed for implementation within a community setting.

METHODS

The study had two phases. The first was a screening phase which identified people at risk of PDM/T2DM through the use of a screening tool that had been developed and validated for use within Primary Care.(11, 12) In the second phase, participants who had been screened and found to have PDM progressed to the cluster RCT. The cluster RCT design has been described in detail elsewhere.(13) The trial randomised practices to avoid the risk of contamination. Ethical approval was sought and the study involved practice level and individual level informed consent. Recruitment took place between May 2009 and June 2011, with follow up data collected up to July 2014.

Practices and participants

Practices in Leicestershire, UK, were recruited and randomised using a computer-generated list 1:1 to either the standard-care or intervention arm by an independent researcher, using stratification by list size (<6,000, ≥6,000), and ethnicity (percentage South Asian <21%, ≥21% - taken from ADDITION-Leicester study (14)) with a block size of four. Practices and participants were informed of their allocation in the results letters after the screening/baseline measurements were complete. Eligible participants were identified from recruited practices via a two-stage screening process. The Leicester Diabetes Practice Risk Score was used in each practice to identify people at high-risk of PDM/T2DM for invitation to screening.(11) The top 10% of patients with the highest score fulfilling the inclusion criteria were invited. The inclusion criteria for screening were aged 40 to 75 if White European, or 25-75 years if South Asian. Participants were excluded if they were unable to give informed consent, pregnant or lactating, had established diabetes or a terminal illness, or if they required an interpreter for a language other than one of the locally used South Asian languages accommodated within this study. All those agreeing to take part received an oral glucose tolerance test (OGTT). Only participants who were identified as having PDM (IFG and/or IGT WHO 1999 criteria (15)) during screening took part in the RCT. In one small practice (list size=1650) no participants were identified with PDM and was excluded.

The screening-visit data formed the baseline assessment for the RCT; participants were followed up at 6, 12, 24 and 36 months.

Interventions

All participants received an information booklet which included information on risk factors for T2DM, and how dietary and lifestyle changes and increased physical activity can prevent progression to T2DM.

Participants in the intervention practices were invited to attend the Let's Prevent programme, (13) which tailors the widely delivered DESMOND structured-education programme into a prevention context. (16, 17)

Let's Prevent was delivered to groups of ten over six hours, either over a full-day or two half-days, by two trained educators. The programme was underpinned by a theoretical basis with a philosophy centred on patient empowerment. The aim was to increase knowledge and promote realistic perceptions of PDM, and to promote health behaviour, with the aims of reducing body weight by 5%, limiting total and saturated fat intake to 30% and 10% of total energy intake respectively, increasing fibre intake and promoting physical activity. The physical activity section incorporated the successful PREPARE structured-education programme,(7) based on providing participants with a pedometer and enabling the formation of personalised step-per-day goals. The content and educational resources used within the programme were further tailored to the need of local South Asian populations, including delivery through interpreters where required. Educators were trained using an accredited pathway, and received ongoing support and quality development to ensure consistent delivery.

Participants were invited to three-hour refresher sessions at 12 and 24 months to reinforce key messages, review risk factors and update action plans. In addition, participants received a 15-minute telephone call every three months from healthcare professionals trained to offer on-going support in behaviour change. Those who did not attend the initial session were not invited to the refresher sessions, but continued to be followed up.

Outcome measures

All outcomes were measured at the participant level. The primary outcome was progression to T2DM during three years. T2DM diagnosis was defined according to WHO 1999 criteria/guidelines.(15) Participants without symptoms of diabetes in whom the initial OGTT showed T2DM were re-called for a second test to confirm the diagnosis. Participants found to

have T2DM at baseline were excluded. Following the update of the WHO diagnostic criteria to include HbA1c (18) we obtained a protocol amendment in January 2013 allowing HbA1c $\geq 6.5\%$ to become part of diagnostic criteria for T2DM within this study. Therefore T2DM was diagnosed using OGTT prior to January 2013, and with either an OGTT or HbA1c post January 2013. Participants and their GP were informed of the results. Diagnosis of T2DM within primary care was also captured by self-report followed by confirmation through GP records. Participants diagnosed with T2DM after baseline remained in the study to complete the questionnaires and other biomedical data, but did not undertake further OGTTs.

A full list of the secondary outcomes assessed at each time point is described elsewhere (13), these included: lipid levels, HbA1c, medical and medication history, blood pressure, weight, waist and body mass index (BMI). Participants also completed a questionnaire containing a number of validated questionnaires which assessed total self-reported physical activity, subsequently reported as metabolic equivalent minutes per week (METS.mins/wk),(19) diet reported as a unit-less fibre, total fat and unsaturated fat score,(20) illness beliefs,(21) anxiety and depression,(22) quality of life(23) and sleep pattern; resource usage data and EQ-5D responses were also collected for the cost-effectiveness analysis.(24) Participants also wore a sealed pedometer (NL-800, New Lifestyles, Inc., Lees Summit, MO, USA) with a seven-day memory during waking hours to provide habitual ambulatory activity (average daily step count derived by summing total accumulated steps and dividing by days worn). For the purposes of this study, at least three valid days of data were required; a valid day constituted at least 10 hours of wear time (25).

Other secondary outcomes included change in cardiovascular risk as calculated by the Framingham risk calculator, and presence of metabolic syndrome as defined by NCEP ATP III.

Sample Size

The sample size takes into account the clustering by GP practice. Assuming a three-year cumulative conversion rate to T2DM of 35% in the standard-care group (equivalent to 117 events per 1000 follow-up years), an intraclass correlation of 0.05, and 17 participants per practice (equal clusters assumed), we needed 280 per group to detect a 40% risk reduction in the intervention group. Allowing for a 25% drop-out rate, a total of 748 participants needed to be recruited.

Statistical analysis

A statistical-analysis plan was agreed before data were available. Practice and participant level characteristics were compared by group, using either means (SD) or medians (IQR) for continuous variables, and counts and percentages for nominal variables. Cluster randomisation gives balance with respect to cluster-level covariates but can lead to imbalance in participant level covariates; therefore differences were assessed using t-tests and chi-squared tests.

Progression to T2DM was analysed on an intention-to-treat basis (ITT). The event rate per 1,000 person years was calculated by group. Participants were censored at the date of their last clinical appointment or at diagnosis of T2DM. Cox proportional hazards models with group as a covariate were fitted; practices were assumed to have the same frailty. Hazard ratios (HR) and 95% confidence intervals were presented. Subgroup analyses were performed by PDM status (IGT, IFG, IGT and IFG, HbA1c 6.0-6.4%).

For all secondary outcomes, participants who developed T2DM during the study had their last value from before their diagnosis carried forward for the remainder of the study. This method was used in a previous similar study.(7) All secondary outcomes were analysed using generalised estimating equation models with an exchangeable correlation structure, which adjusted for clustering. For binary outcomes we used a logit link with a binomial distribution for the outcome, and for continuous outcomes we used an identity link with a normal distribution. The analysis was repeated at each time point. The missing outcomes were not replaced and we derived an average of continuous outcomes over time. This procedure measures the cumulative effect of the intervention and has the maximum number of participants.

Subsidiary analyses were carried out for the main secondary outcomes at 12 and 36 months. The analysis was repeated: (i) excluding those from the intervention group who did not attend the initial Let's Prevent education session (per-protocol); and (ii) imputing any missing values for the secondary outcomes using multiple imputation (ITT). The imputation was carried out using the command MI in Stata. MI replaces missing values with multiple sets of simulated values to complete the data, performs standard analysis on each completed dataset, and adjusts the obtained parameter estimates for missing-data uncertainty using Rubin's rules to combine estimates.(26) Adjustments were not made for multiple testing. All the results

from the planned analyses have been reported and P values interpreted taking into account the overall pattern of the results. Statistical significance was set at 5%. All analyses were conducted using Stata version 13.

RESULTS

Overall, 43 practices were included; ranging in size from 1,650-24,000. The median number of participants with PDM recruited per practice was 23 in the standard-care arm and 17 in the intervention arm; the number recruited per practice ranged from 2-49. In total 880 participants were recruited (433 standard care, 447 intervention, Figure 1). At 36 months 76% of the intervention group attended compared to 79% in the standard-care arm ($p=0.43$). Compared to those who attended at 36 months, non-attenders were more likely to be smokers, and from more socially-deprived locations (Table A.1). Of those participants from practices randomised to the intervention, 101 (22.6%) did not attend the initial education session and were excluded in per-protocol analyses. Compared to those who attended, non-attenders were younger, more likely to be male, from more socially deprived locations, more likely to be smokers, and less physically active (see Table A.2).

At baseline a higher levels of deprivation and smokers were seen in the intervention group (Table 1). Weight ($p=0.0002$), BMI ($p=0.003$) and waist circumference ($p=0.0001$) were significantly higher in the standard-care group compared to the intervention group.

Figure 1 Flow of practices and participants through the trial




Table 1 Baseline characteristics

Data given as mean (SD) unless otherwise stated

	Standard care	Intervention
Individual level		
Number of participants	433	447
Age	63.9 (7.9)	63.9 (7.6)
Male n (%)	278 (64.2)	282 (63.1)
White European, n (%)	363 (84.3)	377 (84.5)
Deprivation, median (IQR)	10.1 (6.3, 18.1)	13.4 (8.4, 24.4)*
Current smoker, n (%)	22 (5.1)	38 (8.5)*
Prescribed statins, n (%)	171 (43.3)	184 (44.2)
Prescribed antihypertensives, n (%)	270 (62.4)	275 (61.5)
History CVD, n (%)	78 (18.0)	75 (16.8)
HbA1c (%)	6.1 (0.4)	6.1 (0.4)
HbA1c (mmol/mol)	42.8 (4.6)	43.2 (4.7)
Fasting glucose	5.6 (0.7)	5.7 (0.7)
2-hour glucose	8.8 (1.6)	8.9 (1.7)
Total cholesterol (mmol/l)	5.1 (1.1)	5.0 (1.0)
HDL cholesterol (mmol/l)	1.4 (0.5)	1.4 (0.5)
LDL cholesterol (mmol/l)	3.0 (0.9)	3.0 (0.9)
Triglycerides (mmol/l)	1.7 (1.0)	1.7 (0.9)
Systolic blood pressure (mmHg)	147.7 (17.7)	147.9 (20.7)
Diastolic blood pressure (mmHg)	86.2 (10.6)	86.6 (11.0)
Heart rate (bpm)	69.1 (12.1)	68.3 (13.1)
Weight (kg)	94.4 (18.9)	89.9 (16.6)*
BMI (kg/m ²)	33.1 (5.8)	32.0 (5.2)*
Waist circumference (cm)	111.3 (13.2)	108.0 (12.4)*
Average steps per day	6308.12 (3094.44)	6137.97 (2791.02)
IFG only, n (%)	51 (11.8)	57 (12.8)
IGT only, n (%)	308 (71.1)	301 (67.3)
IFG and IGT, n (%)	74 (17.1)	89 (19.9)
HbA1c 6.0-6.4% (%)	216 (50.1)	205 (46.7)
CHD 10 year risk***	14.5 (8.6)	14.5 (8.5)

CVD 10 year risk***	20.2 (11.8)	20.3 (11.9)
<hr/>		
Cluster level		
Number of practices	20**	23
<hr/>		
Median participants per practice (IQR)	23 (8, 34)	17 (7, 30)
Range participants per practice	2-41	3-49
Median practice size (IQR)	6932 (4008, 10069)	5429 (3356, 8780)
High South Asian population, n (%)	2 (10.0)	4 (17.4)
<hr/>		

*groups differ significantly (p<0.05)

** One practice randomised to standard care had no eligible participants.

*** Only calculated for those of WE or SA ethnicity between the ages of 35-75.

HDL: High-density lipoprotein; LDL: Low-density lipoprotein; IGT: Impaired glucose tolerance; IFG: Impaired fasting glucose; CHD: Coronary heart disease; CVD: Cardiovascular disease; IQR: Inter-quartile range.

Development of T2DM

131 participants developed T2DM during a median follow-up of three years; this equates to 60.32 events per 1,000 person years (95% CI 50.82, 71.58). Lower rates were seen in the intervention group: 57.60 events per 1,000 person years compared to 63.16 events per 1,000 person years in the standard-care group (Figure A.1). The hazard ratio (HR) showed a non-significant 26% reduced risk of developing T2DM in the intervention arm compared to standard-care ($p=0.18$). The effect was greater (35% reduction) in the per-protocol analysis albeit still non-significant ($p=0.07$) (Table 2). The risk of developing T2DM in the intervention group compared to standard-care was similar across all sub-groups of PDM. The ICC for the development of T2DM was 0.02 (95% CI 0, 0.05).

Table 2 Development of T2DM overall and by PDM diagnosis

HR (95% CI) takes into account clustering

	Standard care	Intervention	HR	95% CI	P value
Intention to treat*			0.74	0.48, 1.14	0.18
Events, n (%)	67 (15.5)	64 (14.3)			
Rate per 1000 py (95% CI)	63.16 (49.71, 80.24)	57.60 (45.09, 73.59)			
Per protocol			0.65	0.41, 1.03	0.07
Events, n (%)	67 (15.5)	51 (14.7)			
Rate per 1000 py (95% CI)	63.16 (49.71, 80.24)	53.04 (40.31, 69.80)			
PDM Sub-group					
IGT alone	34 (11.2)	32 (10.7)	0.79	0.45, 1.38	0.41
IFG alone	7 (14.3)	6 (10.5)	0.52	0.15, 1.83	0.31
IGT and IFG	26 (32.9)	26 (28.3)	0.51	0.22, 1.16	0.11
HbA1c 6.0-6.4	36 (15.2)	27 (11.9)	0.65	0.38, 1.12	0.12

* This is the same as complete case as there are no missing data for the primary outcome

Secondary outcomes

In both groups improvements were seen for many secondary outcomes, see Table 3 for a summary and A.3-A.6 for the full results. A statistically significant reduction of 0.06% in HbA1c was seen in the intervention group compared to the standard-care group when analysing the mean across all time points. Significant reductions in LDL-cholesterol were seen at 12 months and overall. For all other outcomes, apart from systolic blood pressure, a greater improvement was seen in the intervention group than the standard-care group at 36 months, but none of these reached statistical significance. No differences were seen for CVD/CHD risk outcomes or the presence of metabolic syndrome.

Improvements during the study were seen in illness perceptions, quality of life and anxiety in the intervention group compared to the standard-care group. Fat intake was not significantly reduced in the intervention group compared to the standard-care group, but statistically significant increases in unsaturated fat were reported. Although no differences between the intervention and standard-care group were seen in the self-reported levels of activity, a significant reduction in sitting time of 30 minutes per day or more was seen in the intervention group at 12 and 24 months and overall, compared to the standard-care group. There was also an increase in objectively measured average daily step-count in the intervention group of 450-500 steps per day at all time points, with a significant effect seen at 12, 36 months and overall.

Table 3 Secondary outcomes

Coefficients show the mean effect of the intervention compared to standard care adjusted for baseline value and cluster (full table given in Tables S3-6)

	6 months	12 months	24 months	36 months	Overall
Fasting glucose	NR	0.001 (-0.10, 0.10)	-0.06 (-0.16, 0.04)	-0.05 (-0.18, 0.07)	0.0004 (-0.10, 0.10)
2-hour glucose	NR	0.08 (-0.23, 0.39)	-0.07 (-0.37, 0.22)	-0.14 (-0.46, 0.18)	-0.03 (-0.28, 0.22)
HbA1c (%)	-0.07 (-0.12, -0.01)*	-0.04 (-0.10, 0.02)	-0.10 (-0.20, -0.004)*	-0.07 (-0.18, 0.04)	-0.06 (-0.11, -0.01)*
Total cholesterol (mmol/l)	-0.06 (-0.18, 0.05)	-0.07 (-0.16, 0.02)	-0.02 (-0.12, 0.08)	-0.11 (-0.23, 0.02)	-0.06 (-0.14, 0.01)
HDL cholesterol (mmol/l)	0.003 (-0.05, 0.06)	-0.01 (-0.07, 0.05)	0.004 (-0.06, 0.07)	-0.02 (-0.08, 0.05)	0.01 (-0.04, 0.05)
LDL cholesterol (mmol/l)	-0.06 (-0.15, 0.04)	-0.10 (-0.18, -0.02)*	-0.02 (-0.09, 0.05)	-0.09 (-0.19, 0.01)	-0.08 (-0.15, -0.01)*
Triglyceride (mmol/l)	-0.01 (-0.16, 0.14)	0.05 (-0.05, 0.15)	-0.05 (-0.15, 0.05)	-0.06 (-0.17, 0.06)	-0.001 (-0.08, 0.08)
Body weight (kg)	-0.10 (-0.72, 0.51)	-0.27 (-1.17, 0.63)	-0.49 (-1.48, 0.50)	-0.26 (-1.17, 0.65)	-0.10 (-0.85, 0.66)
BMI (kg/m ²)	-0.03 (-0.24, 0.19)	-0.11 (-0.42, 0.21)	-0.14 (-0.50, 0.21)	-0.05 (-0.38, 0.27)	-0.02 (-0.28, 0.25)
Waist circumference (cm)	-0.91 (-2.03, 0.20)	-0.11 (-1.37, 1.15)	-0.82 (-2.03, 0.40)	-0.79 (-1.73, 0.14)	-0.45 (-1.32, 0.42)
Systolic BP (mmHg)	1.17 (-1.45, 3.79)	1.22 (-0.85, 3.30)	-1.26 (-3.79, 1.28)	0.55 (-2.09, 3.19)	0.81 (-0.97, 2.60)
Diastolic BP (mmHg)	-0.22 (-1.90, 1.46)	0.80 (-0.66, 2.26)	-0.37 (-1.92, 1.19)	-0.49 (-2.15, 1.17)	0.24 (-0.82, 1.30)
Heart rate (bpm)	-1.31 (-2.90, 0.28)	-0.61 (-1.84, 0.61)	-0.68 (-2.00, 0.65)	-0.52 (-1.83, 0.78)	-0.66 (-1.58, 0.27)
CHD 10-year risk	-0.18 (-0.84, 0.48)	-0.14 (-0.73, 0.45)	-0.68 (-1.40, 0.04)	-0.23 (-1.07, 0.60)	-0.35 (-0.81, 0.11)
CVD 10-year risk	0.28 (-0.77, 1.32)	0.01 (-0.74, 0.76)	-0.74 (-1.64, 0.15)	0.04 (-1.07, 1.14)	-0.14 (-0.64, 0.35)
Metabolic syndrome†	NR	1.05 (0.78, 1.43)	0.81 (0.60, 1.09)	1.10 (0.83, 1.46)	1.10 (0.83, 1.46)
Illness perception score (BIPQ)‡	-1.46 (-3.13, 0.21)	-2.06 (-4.03, -0.09)*	-2.47 (-4.16, -0.78)**	-1.16 (-2.69, 0.37)	-1.61 (-2.92, -0.30)*
Quality of life score (15D)† †	0.01 (-0.001, 0.01)	0.01 (-0.002, 0.02)	0.01 (-0.002, 0.02)	0.02 (0.01, 0.03)**	0.01 (0.001, 0.02)*
Anxiety score (HADS)‡	-0.21 (-0.57, 0.15)	-0.40 (-0.77, -0.03)*	-0.09 (-0.40, 0.21)	-0.11 (-0.44, 0.23)	-0.28 (-0.54, -0.02)*
Depression score (HADS)‡	-0.08 (-0.42, 0.26)	-0.34 (-0.81, 0.14)	-0.09 (-0.45, 0.27)	-0.05 (-0.44, 0.35)	-0.21 (-0.57, 0.16)

Diet (DINE):					
Fibre intake	-1.69 (-4.68, 1.29)	0.97 (-1.27, 3.21)	-1.64 (-4.68, 1.39)	1.53 (-0.94, 4.00)	-1.01 (-3.11, 1.08)
Fat intake	-1.41 (-4.60, 1.77)	0.45 (-2.62, 3.51)	-0.55 (-4.04, 2.95)	-3.60 (-7.52, 0.31)	-0.72 (-2.92, 1.48)
Unsaturated fat intake	0.18 (-0.12, 0.48)	0.32 (0.05, 0.58)*	0.50 (0.24, 0.76)***	0.38 (0.12, 0.63)**	0.33 (0.15, 0.51)***
Subjective physical activity (IPAQ):					
Total METS	352.71 (-570.24, 1275.65)	447.31 (-220.84, 1115.46)	415.06 (-234.47, 1064.59)	-19.82 (-568.05, 528.41)	428.37 (-175.19, 1031.93)
Sitting time (mins)	-27.26 (-63.34, 8.83)	-25.94 (-49.95, -1.92)*	-38.96 (-66.15, -11.78)**	-20.15 (-43.91, 3.60)	-26.29 (-45.26, -7.32)**
Objective physical activity:					
Average steps per day	591-38 (63.61, 1119.16)*	551.76 (117.27, 986.25)*	466.30 (-65.50, 998.10)	535.76 (12.71, 1058.81)*	498.15 (162.10, 834.20)**
Sleep:					
Hours slept last night	NR	0.04 (-0.15, 0.22)	-0.05 (-0.18, 0.09)	-0.10 (-0.26, 0.06)	-0.05 (-0.18, 0.08)
Average hours asleep in 24 hours	NR	0.10 (-0.16, 0.35)	-0.03 (-0.23, 0.17)	0.11 (-0.06, 0.27)	0.01 (-0.16, 0.18)

HDL: High-density lipoprotein; LDL: Low-density lipoprotein; BMI: Body mass index; IGT: Impaired glucose tolerance; IFG: Impaired fasting glucose; CHD: Coronary heart disease; CVD: Cardiovascular disease; BIPQ: Brief Illness Perception Questionnaire; 15D: 15-dimensional; HADS: Hospital Anxiety and Depression Scale; DINE: Dietary Instrument for Nutrition Education; IPAQ: international physical activity questionnaire; METS: Metabolic equivalents.

*p<0.05, **p<0.01, ***p<0.001

†Data shown OR (95% CI)

≠ higher score reflects a more threatening view of illness

†† higher score reflects better quality of life

‡ higher score reflects worse levels of anxiety/depression

Subsidiary analyses

In the per-protocol analysis, significant reductions at 36 months were seen for fasting (-0.12 mmol/l), 2-hour (-0.35 mmol/l) and HbA1c (-0.11%) in the intervention compared to standard-care (Table 4). The increase in step-count in the intervention group compared to standard-care was increased in the per-protocol analysis. For the intention-to-treat analysis, the interpretation of the results for the secondary outcomes assessed did not change.

Table 4 Key secondary outcomes – Subsidiary analysis

Coefficients show intervention effect adjusted for baseline value and cluster. Complete case – data analysed according to randomised group; those with missing data excluded on a case-by-case basis. Per protocol – those randomised to the intervention who did not attend the initial education are excluded. Intention to treat – data analysed according to randomised group, all randomised participants included. Missing data imputed using multiple imputation.

	Complete case		Per protocol		Intention to treat	
	12 months	36 months	12 months	36 months	12 months	36 months
Fasting glucose	0.001 (-0.10, 0.10)	-0.05 (-0.18, 0.07)	0.03 (-0.14, 0.08)	-0.12 (-0.23, -0.01)*	0.02 (-0.09, 0.13)	-0.02 (-0.13, 0.08)
2-hour glucose	0.08 (-0.23, 0.39)	-0.14 (-0.46, 0.18)	0.03 (-0.30, 0.36)	-0.35 (-0.61, -0.09)**	0.10 (-0.22, 0.42)	-0.10 (-0.45, 0.25)
HbA1c (%)	-0.04 (-0.10, 0.02)	-0.07 (-0.18, 0.04)	-0.04 (-0.10, 0.02)	-0.11 (-0.21, -0.01)*	-0.02 (-0.08, 0.04)	-0.07 (-0.17, 0.04)
CHD 10-year risk	-0.14 (-0.73, 0.45)	-0.23 (-1.07, 0.60)	-0.11 (-0.75, 0.53)	-0.15 (-1.05, 0.75)	-0.16 (-0.81, 0.49)	-0.48 (-1.34, 0.37)
CVD 10-year risk	0.01 (-0.74, 0.76)	0.04 (-1.07, 1.14)	-0.02 (-0.77, 0.73)	0.12 (-1.03, 1.28)	-0.12 (-0.96, 0.72)	-0.55 (-1.50, 0.39)
Metabolic syndrome	1.05 (0.78, 1.43)	1.10 (0.83, 1.46)	0.74 (0.52, 1.05)	0.77 (0.56, 1.04)	1.05 (0.78, 1.43)	1.10 (0.83, 1.46)
Average steps per day	551.76 (117.27, 986.25)*	535.76 (12.71, 1058.81)*	777.48 (336.66, 1218.31)**	634.27 (1419.41, 2665.56)*	576.47 (110.37, 1042.56)*	469.52 (29.47, 909.57)*

CHD: Coronary heart disease; CVD: Cardiovascular disease.

*p<0.05, **p<0.01, ***p<0.001

DISCUSSION

To our knowledge, this is the first study investigating the effectiveness of a T2DM prevention programme within primary care in the UK. We have shown that a pragmatic, low-resource, three-year T2DM prevention programme, based on a six-hour, group-based, structured-education session followed by two annual group-based sessions and nine telephone contacts, can lead to improvements in markers of metabolic health, psychosocial wellbeing, and health behaviour. The primary outcome of the study was reduction in progression to T2DM; although non-significant, a modest 25% reduction in progression was observed in those receiving the education intervention, which increased to 35% when excluding those who did not attend the first education session.

Our study has several strengths and limitations. Strengths include using a rigorous design to evaluate the effectiveness of the programme specially developed for delivery within a multi-ethnic primary care setting. The primary limitation was that this study was underpowered due to the discrepancy between predicted and observed incidence rates of T2DM. The observed incidence rates of 63.16 events per 1,000 person years in the standard-care arm were substantially lower than anticipated, and consistent with those observed in non-intervention settings.(27) This acted to substantially reduce the study power, resulting in wider confidence intervals and a greater likelihood of a type 2 error. In addition, the variation in cluster size was greater than planned (the number of participants recruited per practice ranged from 2-49, further diluting power. However, the estimates of the ICC (0.05) and the inflation for drop out (25%) used were adequate (0.02 and 24% respectively). Although the reduction in the risk of T2DM was not statistically significant, the effect size was similar to the Indian Diabetes Prevention programme, which reported a 28.9% reduction in the risk of T2DM following a lifestyle intervention.(28) Limitations inherent in cluster randomised studies were also observed here, particularly achieving a balance in participant characteristics across groups: important differences at baseline were observed, with the intervention group having higher levels of social deprivation and smoking rates, but with lower levels of BMI and waist circumference. These differences could have acted to confound the result. Finally, the generalizability of the findings should be assessed cautiously. Of those invited for screening, 19% attended.(12) Although this uptake rate is consistent with other studies in similar populations (29, 30) and reflects the difficulty of recruiting a multi-ethnic urban population into prevention studies, it may limit the generalizability of the findings. Higher rates of uptake would be expected in a non-research setting: for example, the NHS Health Checks

programme has 40% uptake.(31) Due to ethical constraints, no data extracted from primary care regarding those invited for screening. Therefore we cannot compare the characteristics of the invited cohort to those who attended to establish if there was any potential for bias. A study of similar design conducted in the same area screening for T2DM found that the 22% who attended screening were older and more likely to be female.(30) Only 23% of the intervention group attended the initial education, ad-hoc analyses suggest the intervention effect can be increased as attendance increases. Future studies should focus on strategies to increase uptake to screening and attendance/compliance with the programme.

We observed several improvements in secondary outcomes. Importantly, there was evidence that the programme reduced threatening perceptions of PDM, anxiety and improved overall quality of life. This is consistent with other structured-education programmes.(16) These benefits were mirrored by modest improvements in health behaviour. For example, the intervention-group reported healthier dietary fat profile, sitting on average for 26 minutes less per day and undertaking 498 more steps per day compared to standard-care. This change equates to an increase of 35 minutes of purposeful walking per week.(25) This is similar to that reported in the Early Activity in Diabetes (ACTID) diet and physical activity intervention for those with newly diagnosed T2DM, which was also conducted in primary care.(32) The protocol defined a priori a number secondary outcomes,(13) this reflects the nature of the intervention, which targets a number of aspects of health and wellbeing. We have not adjusted for multiple testing, which may have increased the type 1 error rate.(33) The results seen here reflect those seen in other similar trials, (28, 34) and have been interpreted in terms of clinical as well as statistical importance.

Our study extends evidence for efficacy of lifestyle interventions in the prevention of T2DM into in a primary care setting. There is now evidence internationally that T2DM prevention programmes can be tailored for, and translated into, primary health care and community settings, with modest short-term effects on markers of health status, such as body weight.(35) However, longer-term studies designed to quantify effectiveness on reducing progression to T2DM are lacking. This has resulted in a lack of evidence-based solutions that might enable primary care organisations to conform to NICE guidance for the prevention of T2DM. (36) By utilising structured education, Let's Prevent was purposefully designed to harness existing infrastructure within routine primary care. Structured education has been recommended in the management of T2DM by NICE since 2003.(37) DESMOND is one of the most prominent

nationally available T2DM structured-education programme, and the only UK programme tested within a multi-centred RCT to quantify effectiveness and cost-effectiveness.(16, 38) Here we show that this approach can be adapted to the prevention of T2DM within a diverse multi-ethnic PDM population whilst using less than 25% of the contact time seen in other efficacy trials. Future research is needed to investigate how the approach used in Let's Prevent can be tailored to individual preferences concerning the frequency and format of contact. In particular, utilising web-based platforms is likely to receive a growing focus in the future.

A separate paper assesses the cost effectiveness of the intervention. In brief, this showed the education programme was associated with higher costs (£168) and higher quality of life (0.046 QALYs) compared to the standard care group over three years. Therefore, the Let's Prevent programme is likely to be cost effective at a willingness to pay threshold of £20,000 per QALY gained.(39)

CONCLUSION

We have shown that a relatively low-resource, pragmatic T2DM prevention programme can lead to modest improvements to biomedical, lifestyle and psychosocial outcomes without significantly reducing the risk of T2DM. The findings have important implications for future research and primary care.

Funding and Ethics

This research was funded by National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0606-1272). This report/article presents independent research commissioned by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0606-1272). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Ethical approval was granted for this project by the NHS East Midlands Ethics Committee.

Acknowledgements

The project was supported by the University of Leicester Clinical Trials Unit, the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM), and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester.

Conflicts of interests

Laura J Gray, Jacqui Troughton, Alastair Gray, Jaakko Tuomilehto and Azhar Farooqi declare no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work. Melanie J Davies, Kamlesh Khunti and Thomas Yates declare no support from any organisation for the submitted work and no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; MJD, KK and TY were members (KK chair) of the NICE PH 38 (Preventing type 2 diabetes: risk identification and interventions for individuals at high risk) Programme Development Group.

Contributor statements

MJD Principal Investigator for the Let's Prevent Programme Grant, initiated the project, commented on drafts of the paper and approved the final version. MJD is the guarantor for the paper and affirms that the manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that

any discrepancies from the study as planned (and, if relevant, registered) have been explained. LJG wrote the statistical analysis plan, cleaned and analysed the data, and drafted and revised the paper. JT developed the Let's Prevent Programme, commented on drafts of the paper and approved the final version. AG had input into the design of the study, the collection of data, led the cost effectiveness analysis, and commented on drafts of the paper and approved the final version. JTu had input into the design of the study and commented on drafts of the paper and approved the final version. AF had input into the design of the study, commented on drafts of the paper and approved the final version. KK and TY had input into the design and running of the study, commented on drafts of the paper and approved the final version.

The Let's Prevent Diabetes Team: Keith Abrams, University of Leicester, Leicester. Dariush Ahrabian, University of Oxford. Sayjal Amin, University Hospitals of Leicester, Leicester. Mary Bancroft, Hockley Farm Medical Practice. Janette Barnett, University Hospitals of Leicester, Leicester. Hannah Berkeley, University Hospitals of Leicester, Leicester. Danielle Bodicoat, University of Leicester, Leicester. Michael Bonar, University Hospitals of Leicester, Leicester. Louise Boyles, University Hospitals of Leicester, Leicester. Paul Bray, University Hospitals of Leicester, Leicester. Nichola Cairns, University Hospitals of Leicester, Leicester. Sandra Campbell, University Hospitals of Leicester, Leicester. Marian Carey, University Hospitals of Leicester, Leicester. Patrice Carter, University of Leicester, Leicester. Sudesna Chatterjee, University Hospitals of Leicester, Leicester. Pauline Cowling, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield. Carolyn Currie, University Hospitals of Leicester, Leicester. Heather Daly, University Hospitals of Leicester, Leicester. Alison Dunkley, University of Leicester, Leicester. Sue Enright, University Hospitals of Leicester, Leicester. Stephanie Goldby, University Hospitals of Leicester, Leicester. Geri Gray, University Hospitals of Leicester, Leicester. Colin Greaves, University of Exeter Medical School, Exeter. Joe Henson, University Hospitals of Leicester, Leicester. Stephen Hiles, University Hospitals of Leicester, Leicester. Sian Hill, University Hospitals of Leicester, Leicester. Jayne Hill, University Hospitals of Leicester, Leicester. Hannah Holdsworth, University Hospitals of Leicester, Leicester. Rosie Horne, University of Leicester, Leicester. Zin Zin Htike, University Hospitals of Leicester, Leicester. Shenaz Jamal, University Hospitals of Leicester, Leicester. Janet Jarvis, University Hospitals of Leicester, Leicester. Carolyn Johnson, University Hospitals of Leicester, Leicester. Janet Jones, University Hospitals of Leicester, Leicester. Kenneth Jones, University Hospitals of

Leicester, Leicester. Sabera Khan, University Hospitals of Leicester, Leicester. Anita Khulpateea, University Hospitals of Leicester, Leicester. Jose Leal, University of Oxford. Judith Leonard, University Hospitals of Leicester, Leicester. Hamidreza Mani, University Hospitals of Leicester, Leicester. Lorraine Martin-Stacey, University Hospitals of Leicester, Leicester. Val Morgan, University Hospitals of Leicester, Leicester. Frances Morris, University Hospitals of Leicester, Leicester. Samiul Mostafa, University Hospitals of Leicester, Leicester. Alison Northern, University Hospitals of Leicester, Leicester. Kayleigh O'Brien, University Hospitals of Leicester, Leicester. Hersha Patel, University Hospitals of Leicester, Leicester. Naina Patel, University of Leicester, Leicester. Rachel Plummer, University Hospitals of Leicester, Leicester. Sheila Porter, University Hospitals of Leicester, Leicester. Mo Radia, University Hospitals of Leicester, Leicester. Kathryn Realf, University Hospitals of Leicester, Leicester. Dean Richmond, University Hospitals of Leicester, Leicester. Clare Russell, University of Leicester, Leicester. Rebecca Saker, University Hospitals of Leicester, Leicester. Jane Sennet, University Hospitals of Leicester, Leicester. David Sheppard, Saffron Group Practice, Leicester. Rebecca Spong, University of Leicester, Leicester. Bernie Stribling, University Hospitals of Leicester, Leicester. Margaret Stone, University of Leicester, Leicester. Nick Taub, University of Leicester, Leicester. David Webb, University of Leicester, Leicester. Emma Wilmott, University Hospitals of Leicester, Leicester. Carolina Wilson, University Hospitals of Leicester, Leicester. Panna Wilson, University Hospitals of Leicester, Leicester.

Participating Practices: Dr Y B Shah & Partners, Silverdale Medical Centre. Leicester Medical Group Aylestone Rd Medical Centre. Leicester Medical Group, Walnut Street Medical Centre. Dr J M Fry & Partner (Dr Clay), Rushey Mead Health Centre. Dr Patchett & Partners, Groby Road Medical Centre. Leicester Medical Group, Thurmaston Health centre. Dr Mojaria, Broadhurst Street Medical Practice. Dr Clay & Partners, The Banks Surgery. Dr Brunskill & Partners, Pinfold Medical Practice. Dr Barlow & Partners, Quorn Medical Centre. Dr Clay & Partners, Cottage Surgery. Dr Joshi (Dr Astles & Partners), Willowbrook Medical Centre. Dr G Singh Pasley Road Health Centre. Dr Ryan & Partners, Woodbrook Medical Centre. Dr Lennox & Partner, St Matthews Medical Centre. Dr Prasad, Clarendon Park Rd Health Centre. Dr G C Ackerley & Partners (Dr Bandrapalli), Beaumont Lodge previously known as Heatherbrook (Astill Lodge) Surgery (also site at Baxters Close). Dr Trzcinski & Partners, Markfield Medical Centre. Dr Lewis & Dr Patel, Whitwick Health Centre. Dr Davenport & Partners, Newbold Verdon Medical Practice. Dr Wilmott & Partners,

Castle Mead Medical Centre. Dr Azar Farooqi, East Leicester Medical Practice. Dr Wilson & Partners, The Old School Surgery. Dr Bennett & Partners, Market Harborough Medical Centre. Dr D A Nandha, Evington Medical Centre. Dr Maini & Dr Roshan, The Willows Medical Centre. Dr Davies & Partners, Ashby Health Centre. Dr Palin (Dr Prideaux & partners), Bushloe End Surgery. Dr Ghatora, Shepshed Health Centre. Dr Woods & Partners, Hugglescote Surgery. Dr S Mansingh & Dr SK Dey, St Peters Health Centre. The Practice Asquith, Asquith Surgery. Dr H Mukadam, Fosse Medical Centre. The Practice Cross Street. Dr Bhutani & Partners, Enderby Medical Centre. The Practice Rushey Mead. The Practice - Sayeed Medical Centre. Dr JC Reynolds & Partners (Dr Graham Johnson), The Wycliffe Medical Practice, Lutterworth Medical Centre. Dr Pathak/Dr Roshan, Hazelmere Medical Centre. Dr B W Kinsella & Partners Hockley Farm Heath & Social Care Centre. Dr Shafi, Briton Street Surgery. Dr Shafi - Westcotes 1, Westcotes GP Surgery W1. Dr Shafi - Westcotes 2 Westcotes GP Surgery W2. Dr Panton & Partners Oakmeadow Surgery.

REFERENCES

1. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. *BMJ*. 2001;322(7299):1389-93.
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. *Diabet Med*. 2012;29(7):855-62.
3. NHS. Five year forward view. 2014.
4. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. *BMJ*. 2007;334(7588):299.
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of Type 2 Diabetes Mellitus by changes in lifestyle among subjects with Impaired Glucose Tolerance. *New England Journal of Medicine*. 2001;344(18):1343-50.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine*. 2002;346(6):393–403.
7. Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education programme aimed at promoting walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. *Diabetes Care*. 2009;32(8):1404-10.
8. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC. The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. *Metabolism* 1997;46(12 Suppl 1):50-5.
9. Oldroyd JC, Unwin NC, White M, Mathers JC, Alberti KGMM. Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. *Diabetes Research and Clinical Practice*. 2006;72(2):117-27.
10. Bhopal RS, Douglas A, Wallia S, Forbes JF, Lean MEJ, Gill JMR, et al. Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. *The Lancet Diabetes & Endocrinology*. 2014;2(3):218-27.
11. Gray LJ, Davies MJ, Hiles S, Taub NA, Webb DR, Srinivasan BT, et al. Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. *Diabetologia*. 2012;55(4):959-66.
12. Gray LJ, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*. 2012;55(12):3238-44.
13. Gray LJ, Khunti K, Williams S, Goldby S, Troughton J, Yates T, et al. Let's Prevent Diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. *Cardiovascular Diabetology*. 2012.
14. Webb DR, Khunti K, Srinivasan B, Gray L, Taub N, Campbell S, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. *Trials*. 2010;11:16.
15. World Health Organisation. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Report. Geneva: World Health Organisation, 1999.

16. Davies M, Heller S, Skinner T, Campbell M, Carey M, Craddock S, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *British Medical Journal* 2008;336(7642):491-5.
17. Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. *BMJ*. 2010;341:c4093.
18. World Health Organisation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Geneva: 2011.
19. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. *Medicine and Science in Sports and Exercise*. 2003;35:1381-95.
20. Roe L, Strong C, Whiteside C, Neil A, Mant D. Dietary intervention in primary care: Validity of the DINE method for diet assessment. *Family practice* 1994;11:375-81.
21. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *Journal of Psychosomatic Research*. 2006;60:631-7.
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 2006;67:361-70.
23. Sintonen H, Pekurinen M. A fifteen-dimensional measure of health-related quality of life (15D) and its applications. In: Walker SR, Rosser RM, editors. *Quality of Life Assessment: Key Issues in the 1990s*. Dordrecht: Kluwer Academic Publishers; 1993. p. 185-95.
24. Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire. In: Preedy VR, Watson RR, editors. *Handbook of Disease Burdens and Quality of Life Measures* New York: Springer; 2010. p. 87-99.
25. Tudor-Locke C, Bassett DR. How many steps/day are enough? Preliminary pedometer indices for public health. *Sports Med*. 2004;34:1-8.
26. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. New York: John Wiley and Sons; 2004.
27. Morris DH, Webb D, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. *Diabetologia* 2013;56(7):1489-1493.
28. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) *Diabetologia*. 2006;49(2):289-97.
29. Aujla N, Eborall HC, Stone M, Taub N, Davies MJ, Khunti K. Barriers to practice and patient recruitment to primary care based diabetes screening studies. *Diabetic Med* 2010;27(Suppl. 1):371.
30. Webb DR, Gray LJ, Khunti K, Srinivasan B, Taub N, Campbell S, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. *In Press Diabetologia* 2011 Jun 3. 2011.
31. Dalton ARH, Bottle A, Okoro C, Majeed A, Millett C. Uptake of the NHS Health Checks programme in a deprived, culturally diverse setting: cross-sectional study. *Journal of Public Health*. 2011;doi:10.1093.
32. Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ, et al. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. *The Lancet*. 378(9786):129-39.

33. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? *BMJ : British Medical Journal*. 2001;322(7292):989-91.
34. Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. *Diabetes Care*. 2003;26(12):3230-6.
35. Dunkley A, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations. A Systematic Review and Meta-analysis. *Diabetes Care*. 2014;37:922-33.
36. National Institute of Health and Clinical Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. London: NICE, 2012.
37. National Institute for Health and Clinical Excellence. Guidance on the use of Patient Education Models for Diabetes (Technology Appraisal 60) London: NICE, 2003.
38. Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis 2010 2010-08-20 12:28:44.
39. Leal J, Ahrabian D, Gray AM. Cost effectiveness of a pragmatic structured education intervention for type 2 diabetes: economic evaluation of data from the Let's Prevent trial Submitted to *BMJ*. 2015.